China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal.
'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.'
The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January.
A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023.
Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals.
China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion.
Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said.
Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings.
Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%.
Still, some say the rally may be getting stretched.
'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month.
Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote.
While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong.
Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms.
Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York.
With assistance from Dong Lyu.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
28 minutes ago
- First Post
Chinese nationals attacked in Pakistan, Beijing puts touring Asim Munir in a spot over security lapses
In the wake of continuing attacks on Chinese nationals and projects in Pakistan, China conveyed strong displeasure to visiting Pakistan army chief Asim Munir and pressed him to take action against anti-China groups on its soil. read more Confident from his visit to Washington DC, Pakistani army chief Asim Munir would have thought of having a victory lap in Beijing. Instead, he received a dressing down from Chinese Foreign Minister Wang Yi over continuing attacks on Chinese nationals and businesses in Pakistan. In recent years, armed groups in Pakistan, such as the Baloch Liberation Army (BLA), have mounted several attacks on Chinese projects under the China-Pakistan Economic Corridor (CPEC) and Chinese nationals living in the country. China has repeatedly called Pakistan to rein in such groups, but the regime has failed to prevent such attacks — Pakistan has failed to prevent attacks against its own personnel as well. STORY CONTINUES BELOW THIS AD Wang told Munir on Thursday that it is his hope that 'the Pakistani military will continue to make all-out efforts to ensure the safety of Chinese personnel, projects and institutions in Pakistan', according to a readout carried by state-owned Xinhua news agency. Even as the two countries mentioned the usual cliches of being iron-clad brothers with an all-weather relationship, Wang's tone in repeated statements made it clear that the Communist Party is not pleased with the state of affairs in Pakistan. After all, the Gwadar port, described as the crown jewel of the CPEC, which itself is central to Xi Jinping's brainchild Belt and Road Initiative (BRI), has failed to take off even after billions of dollars of investment over the past decade.
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
India flexible on Chinese investments in electronics: Govt source
This came as Dixon Technologies has received approval from the Indian government to form a joint venture (JV) with Chinese peer Longcheer Press Trust of India New Delhi India is flexible for collaboration of domestic companies with Chinese, especially electronics, a government source said on Friday. Around 60 per cent of electronics manufacturing happens in China, and hence, it is not easy to ignore it, the source added. "Things are easing (between India and China). There are signals. Tourist visas have been opened. In electronics, 60 per cent of manufacturing takes place in China. So, there has to be some sort of collaboration," the sources said. He was replying to a question on government approval for the Dixon joint venture with Chinese companies. Dixon Technologies has received approval from the Indian government to form a joint venture (JV) with Chinese peer Longcheer. Dixon has been reaching out to several Chinese companies for joint ventures. It has signed separate agreements with Chinese electronic component firms -- Chongqing Yuhai Precision Manufacturing Co Ltd and the Indian arm of Kunshan Q Technology -- for manufacturing and sales of electronic components used in electronic devices like mobile phones and laptops, among others. The company's JV with Chinese smart devices maker Vivo is also in the works. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Mint
28 minutes ago
- Mint
Iran Meets UK, France and Germany for Nuclear Talks
(Bloomberg) -- Iranian and European officials held nuclear talks in Istanbul on Friday as tensions simmer over Tehran's nuclear program after it was targeted by a US military strike last month. Diplomats from the Islamic Republic met with counterparts from the UK, France and Germany — the so-called E3 bloc of top European economies — at around 10:30 a.m. local time to try and ease a standoff over Iran's atomic activities. The talks come about a month after the US bombed three key nuclear sites in Iran, triggering a break in international inspections of its atomic activities and raising questions over the whereabouts of its stockpile of enriched uranium. The strike also derailed separate nuclear negotiations between the Islamic Republic and the Trump administration. The E3 helped broker a 2015 nuclear deal — known formally as the Joint Comprehensive Plan of Action — with Iran that imposed strict limits on Tehran's atomic work in exchange for sanctions relief. Friday's talks are important because they could delay any effort by the Europeans to 'snap back' broad United Nations sanctions that were lifted as part of that accord. French Foreign Minister Jean-Noël Barrot last week announced the possibility of reimposing the sanctions by the end of August if Iran fails to reach a deal limiting its nuclear program. Iran's Foreign Minister Abbas Araghchi has said that the E3 has lost any right to invoke the JCPOA's snapback mechanism, which expires in October, because it failed to meet its own obligations under the agreement after US President Donald Trump withdrew from it seven years ago. On Wednesday, Iran's Deputy Foreign Minister said Tehran has 'not ruled out' withdrawing from the Treaty on the Non-Proliferation of Nuclear Weapons if the UN were to reimpose sanctions. 'That's still on the table,' Kazem Gharibabadi, who's attending the Istanbul talks, told reporters. 'I'm quite confident that if the snapback is triggered, Iran will not show more restraint in this regard,' he said. --With assistance from Patrick Sykes. (Updates lead to reflect talks have started.) More stories like this are available on
